Pediatrix Medical Group (NYSE:MD) Rating Lowered to Buy at Wall Street Zen

Pediatrix Medical Group (NYSE:MD) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their price target for the stock from $27.00 to $28.00 in a report on Wednesday, August 19th. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a research note on Friday, May 8th. UBS Group lifted their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Weiss Ratings downgraded Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 25th. Finally, Truist Financial boosted their target price on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Six analysts have rated the stock with a Hold rating, According to MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average target price of $26.60.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $27.03 on Friday. The firm’s 50 day simple moving average is $26.32 and its 200 day simple moving average is $23.38. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of 12.93 and a beta of 0.64. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. Pediatrix Medical Group has a 1 year low of $15.69 and a 1 year high of $27.94.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The business had revenue of $487.78 million during the quarter, compared to the consensus estimate of $478.49 million. During the same period in the previous year, the business earned $0.53 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. As a group, research analysts expect that Pediatrix Medical Group will post 2.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MD. Global Retirement Partners LLC increased its holdings in Pediatrix Medical Group by 68,250.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after purchasing an additional 1,365 shares in the last quarter. Transamerica Financial Advisors LLC bought a new position in Pediatrix Medical Group in the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pediatrix Medical Group during the fourth quarter valued at about $33,000. Nykredit A S acquired a new stake in shares of Pediatrix Medical Group during the second quarter valued at about $35,000. Finally, TD Private Client Wealth LLC bought a new stake in shares of Pediatrix Medical Group during the fourth quarter worth about $39,000. 97.71% of the stock is currently owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.